Amgen strikes out for the Horizon
Amgen sees off Sanofi and J&J to clinch the rare disease player for $28bn, ensuring that the M&A year ends with a bang.
Precision pays off for Prometheus
Strong mid-stage data defy doubts following rival Pfizer’s spin off.
Burned by Palforzia, Nestlé retreats from its pharma experiment
The chocolate-to-vitamins giant discovers that launching a drug is hard. Should its biopharma partners be worried?
Pfizer hands another asset to Roivant
Does yesterday’s deal with Roivant mean the pharma giant is cooling on TL1A targeting? And what about Prometheus?
Nimbus hopes to best Bristol’s Sotyktu
Nimbus aims to push Tyk2 inhibition to the limit with its more selective project, but others have a similar idea.
Bispecifics move beyond cancer
Hitting two targets with one molecule is all the rage in oncology, but Roche and others have taken this work into other disease areas.
J&J’s $5bn projects have much to prove
The group highlighted Carvykti, nipocalimab and milvexian among its potential mega-blockbusters.
